Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for EBV-positive diffuse large B-cell lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
The classification itself says the boundary between this entity and a lymphoma arising from an ageing immune system is arbitrary, and nobody has defined immune senescence in a way that could settle it.
The virus is present in the tumour and no treatment aims at it. Virus-specific T cells and other approaches used after transplant have not been tested here.
Almost all of the original evidence came from east Asia, and the frequency in European and North American populations is several times lower, so the entity's natural history outside Asia rests on small series.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
In situ hybridisation for Epstein-Barr-encoded RNA on the biopsy. The European series that put the frequency at 3.1 per cent found that no morphological or immunohistochemical feature reliably identified the positive cases, and recommended running the stain on every new diffuse large B-cell lymphoma in a person over 50. Necrosis and CD30 expression are common in positive cases but neither is specific enough to select who to test.
WHO-HAEM5 renamed the entity EBV-positive diffuse large B-cell lymphoma and stated that where it ends and lymphoma of immune deficiency and dysregulation begins is not yet settled.
A direct comparison found the virus in 7 per cent of 136 Mexican diffuse large B-cell lymphomas against 2 per cent of 169 German ones, with the Mexican patients a decade younger at diagnosis.
The fourth edition of the WHO classification added EBV-positive diffuse large B-cell lymphoma of the elderly, largely on the strength of east Asian series.